Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.33 USD
Change Today -0.62 / -5.66%
Volume 706.9K
INFI On Other Exchanges
As of 8:10 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

780 Memorial Drive

Cambridge, MA 02139

United States

Phone: 617-453-1000

Fax: 617-453-1001

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the discovery, development, and delivery of medicines to people with difficult-to-treat diseases. Product Candidates IPI-145, the company’s main product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K, which the company is investigating in both hematologic malignancies and inflammatory diseases. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity. The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in white blood cells, where they have distinct and mostly non-overlapping roles in immune cell development and function. The company has launched DUETTS, a worldwide investigation of IPI-145 in blood cancers. As part of the DUETTS program, the company is conducting DYNAMO, a Phase 2, open-label, single arm study evaluating the safety and efficacy of IPI-145 dosed at 25mg BID in approximately 120 patients with indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma (FL), marginal zone lymphoma and small lymphocytic lymphoma (or SLL), whose disease is refractory to radioimmunotherapy or both rituximab and chemotherapy. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IPI-145 for the potential treatment of FL, the most common subtype of iNHL. Also under the DUETTS program, the company is also conducting DUO, a randomized, monotherapy Phase 3 study of IPI-145 in approximately 300 patients with relapsed/refractory chronic lymphocytic leukemia (CLL). The company is also conducting an ongoing Phase 1, open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics and clinical activity of IPI-145 in patients with advanced hematologic malignancies. The dose escalation portion of the trial is complete, with the maximum tolerated dose defined as 75 mg twice daily, or BID. In 2014, the company intends to initiate DYNAMO+R, a Phase 3 study of IPI-145 dosed at 25 mg BID in combination with rituximab in patients with relapsed/refractory iNHL, as well as a Phase 2 study of IPI-145 in treatment-naïve patients with iNHL. Inflammation and Autoimmune Diseases The company has completed a Phase 1, randomized, double-blind, placebo-controlled trial of IPI-145 in healthy adult subjects designed to support the development of IPI-145 in inflammatory and autoimmune diseases. The company is in the process of conducting a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety and pharmacokinetics of IPI-145 in patients with rheumatoid arthritis (RA), which the company refers to as the ASPIRA trial. The company is also conducting a Phase 2a randomized, double-blind, placebo-controlled trial of IPI-145 in patients with mild, allergic asthma. The company is also developing its second PI3K product candidate, a potent, oral inhibitor of PI3K-delta and gamma which the company refers to as IPI-443. Intellectual Property The company has five issued or allowed U.S. patents covering IPI-145 and/or other molecules related to its PI3K program, which expire on various dates between 2029 and 2031, excluding any patent term extension. In addition, the company has approximately 170 patents and patent applications pending worldwide related to its PI3K program. Research and Development The company’s research and development group is focusing on drug discovery, preclinical research, clinical trials and manufacturing technologies. The company’s research and development expenses for the year ended December 31, 2013, included approximately $99.8 million. Strategic Alliances In 2010, the company entered into a development and license agreement with Intellikine, Inc., or Intellikine, under which it obtained rights to discover, develop and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K, including IPI-145. Significant Events In September 2014, Infinity Pharmaceuticals, Inc. and AbbVie Inc. announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INFI:US $10.33 USD -0.62

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.02 USD +0.07
Curis Inc $3.28 USD -0.03
Evotec AG €3.33 EUR +0.274
Exelixis Inc $3.49 USD -0.27
GlaxoSmithKline SAE £11.50 EGP 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation INFI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at